Please use this identifier to cite or link to this item:
|Title:||Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse|
|Authors:||Verschoyle, Richard D.|
Steward, William P.
Gescher, Andreas J.
|Citation:||Cancer Chemotherapy and Pharmacology, 2008, 62 (2), pp. 369-372.|
|Abstract:||Silibinin is a flavonolignan extracted from milk thistle with cancer chemopreventive activity in preclinical models of prostate and colorectal cancer. A milk thistle extract, of which silibin is a major component, has recently been shown to exacerbate mammary carcinogenesis in two rodent models. We tested the hypothesis that consumption of silibinin or silipide, a silibinin formulation with pharmaceutical properties superior to the unformulated agent, affect breast cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma mouse model. Mice received silibinin or silipide (0.2% silibinin equivalents) with their diet from weaning, and tumour development was monitored by weekly palpation and the number and weight of neoplasms at the end of the experiment. Intervention neither promoted, nor interfered with, tumour development. The result suggests that promotion of carcinogenesis is not a feature of silibinin consistent across rodent models of mammary carcinogenesis.|
|Description:||This paper was published as Cancer Chemotherapy and Pharmacology, 2008, 62 (2), pp. 369-372. It is available from http://www.springerlink.com/content/6320020g83886223/. DOI: 10.1007/s00280-007-0611-8|
Metadata only entry
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Files in This Item:
There are no files associated with this item.
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.